Remora 300mg Review

Remora tablets, containing the active substance Roxithromycin at 150 mg per film-coated tablet, are a semisynthetic a med belonging to the macrolide group. Manufactured by Nobel Ilac Sanayii And Ticaret, A.S. (Turkey), Remora functions by disrupting intracellular protein synthesis in microorganisms, exhibiting a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations. It demonstrates activity against a range of gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, and methicillin-sensitive strains of Staphylococcus aureus. Furthermore, it is effective against gram-negative bacteria such as Moraxella catarrhalis, and against atypical pathogens like Mycoplasma pneumoniae, Ureaplasma urealyticum, and Chlamydia spp. While its activity against Haemophilus influenzae is less pronounced than erythromycin, and it shows low activity against Mycoplasma hominis, it is important to note that Pseudomonas spp., Enterobacter spp., and Acinetobacter spp. are resistant to roxithromycin. Pharmacokinetically, Remora is rapidly absorbed from the gastrointestinal tract after oral administration, appearing in blood serum within 15 minutes. It is more stable in the acidic environment of the stomach compared to other macrolides, and its absorption is not affected by food intake. Peak plasma concentration (Cmax) is achieved in 1.5-2 hours. Roxithromycin effectively penetrates various tissues, particularly the lungs, tonsils, and prostate, and also enters neutrophils and monocytes, enhancing their phagocytic activity. It is highly bound to plasma proteins (96%) and is partially metabolized in the liver. The majority of the active substance is excreted unchanged in the feces, with smaller amounts eliminated by the kidneys and lungs. The half-life in adults with normal renal function is approximately 10.5 hours, allowing for once or twice daily dosing. Remora is indicated for infectious and inflammatory diseases caused by susceptible microorganisms. These include a broad spectrum of infections affecting the upper and lower respiratory tract, such as acute and chronic sinusitis, pharyngitis, tonsillitis, laryngitis, tracheitis, and various forms of pneumonia, including those caused by Mycoplasma pneumoniae and Chlamydia. It is also prescribed for skin and soft tissue infections like impetigo, cutaneous abscesses, furuncles, carbuncles, cellulitis, and pyoderma, as well as non-gonococcal urethritis and post-traumatic wound infections. The recommended dosage for adults is 150 mg twice daily (every 12 hours) or 300 mg once daily, to be taken 15 minutes before meals or on an empty stomach. Dosage adjustments are necessary for patients with hepatic or severe renal insufficiency, where the recommended dose is 150 mg every 24 hours. For children, the daily dose ranges from 5-8 mg/kg, divided into two doses, depending on the pathogen and severity of the infection. Potential adverse reactions primarily affect the digestive system, including nausea, vomiting, epigastric pain, diarrhea, anorexia, flatulence, and transient increases in liver enzymes. Rarely, more severe issues like impaired liver function, cholestatic hepatitis, or pancreatitis may occur. Allergic reactions can manifest as urticaria, rash, itching, angioneurotic edema, bronchospasm, or more severe conditions like Stevens-Johnson syndrome. Central and peripheral nervous system effects may include headache, dizziness, and paresthesia. Other rare side effects include candidiasis, general malaise, tinnitus, and disturbances of taste and/or smell. Remora is contraindicated in individuals with severe liver dysfunction, those concurrently using ergot alkaloids with vasoconstrictive effects, and patients with hypersensitivity to roxithromycin or other macrolides. Caution is advised for use in patients with mild to moderate liver dysfunction, impaired renal function, and during pregnancy and lactation, as adequate safety studies are limited, though animal studies showed no mutagenic or embryotoxic effects. Special precautions include monitoring for superinfection or pseudomembranous colitis, and careful co-administration with drugs like terfenadine and astemizole. Drug interactions can occur with indirect meds (potentiating effect), ergot preparations (risk of ergotism), digoxin (increased absorption), midazolam, triazolam, theophylline, cisapride, astemizole, terfenadine (potential increase in plasma concentrations), and cyclosporine (slight increase in blood concentration and toxicity). Storage instructions specify keeping the tablets between 2°C and 25°C, protected from light and out of reach of children. Remora is a prescription-only medication (Rx Only), and the provided information is for educational purposes, not a substitute for professional medical advice.